fingolimod hydrochloride has been researched along with Lymphoma in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| de Aguiar, PHP; Duarte, JÁ; Finkelsztejn, A; Franceschini, PR; Morillos, MB; Piccini, CD | 1 |
| Hsieh, TY; Lin, JC; Lu, MC; Shih, YL | 1 |
| Azimi, A | 1 |
| Lee, YS; Magae, J; Matsuda, T; Mizuta, N; Nakajima, H | 1 |
| Lee, YS; Magae, J; Nakajima, H; Tsuruga, M | 1 |
| Amari, M; Amemiya, H; Chiba, K; Enosawa, S; Hoshino, Y; Kakefuda, T; Li, XK; Mitsusada, M; Naoe, S; Shinomiya, T; Suzuki, S; Takahara, S | 1 |
| Fujiwara, I; Matsuda, T; Mizuta, N; Nakajima, H; Oka, T | 1 |
7 other study(ies) available for fingolimod hydrochloride and Lymphoma
| Article | Year |
|---|---|
Primary central nervous system lymphoma in a patient with multiple sclerosis using fingolimod.
Topics: Central Nervous System; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphoma; Multiple Sclerosis | 2023 |
Flare of hepatitis B virus after fingolimod treatment for relapsing and remitting multiple sclerosis.
Topics: Cost-Benefit Analysis; Fingolimod Hydrochloride; Hepatitis B virus; Humans; Immunosuppressive Agents; Lymphoma; Multiple Sclerosis; Neoplasm Recurrence, Local | 2020 |
Hypothesis: Fingolimod explores new horizons in treatment of lymphoma.
Topics: Antineoplastic Agents; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Immunotherapy; Lymphocyte Activation; Lymphoma; Models, Immunological | 2016 |
Different mechanisms for membrane and nuclear damages in apoptosis induced by an immunosuppressant, FTY720.
Topics: Animals; Apoptosis; Caspase 3; Caspase Inhibitors; Caspases; Cell Membrane; Cell Nucleus; Dose-Response Relationship, Drug; Enzyme Inhibitors; fas Receptor; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Jurkat Cells; Lymphoma; Mice; Propylene Glycols; Sphingolipids; Sphingosine; Tumor Cells, Cultured | 2002 |
Elimination of cell-cycle regulators during caspase-3-dependent apoptosis caused by an immunosuppressant, FTY720.
Topics: Animals; Apoptosis; Caspase 3; Caspase Inhibitors; Caspases; Cell Cycle; Cell Cycle Proteins; Cell Differentiation; Cell Line; Enzyme Activation; fas Receptor; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Isoenzymes; Lymphoma; Mice; Oligopeptides; Proliferating Cell Nuclear Antigen; Propylene Glycols; Retinoblastoma Protein; Sphingosine; T-Lymphocytes; Transcription Factors; Transfection | 2003 |
Induction of lymphocyte apoptosis and prolongation of allograft survival by FTY720.
Topics: Animals; Apoptosis; Cell Line; Creatinine; Cyclosporine; Dogs; Fingolimod Hydrochloride; Graft Survival; Humans; Immunosuppressive Agents; Kidney Transplantation; Lymphocytes; Lymphoma; Male; Mice; Mice, Mutant Strains; Neoplasm Transplantation; Propylene Glycols; Sphingosine; Time Factors; Transplantation, Homologous; Tumor Cells, Cultured | 1996 |
Caspase requirement for the apoptotic death of WR19L-induced by FTY720.
Topics: Animals; Apoptosis; Caspase 1; Caspase 2; Caspases; Cell Nucleus; Cysteine Endopeptidases; Dose-Response Relationship, Drug; Enzyme Activation; Fingolimod Hydrochloride; Immunosuppressive Agents; Kinetics; Lymphoma; Mice; Propylene Glycols; Proteins; Sphingosine; Tumor Cells, Cultured | 1998 |